Ixekizumab
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pyoderma Gangrenosum
Conditions
Pyoderma Gangrenosum
Trial Timeline
May 4, 2017 → Aug 16, 2018
NCT ID
NCT03137160About Ixekizumab
Ixekizumab is a phase 2 stage product being developed by Eli Lilly for Pyoderma Gangrenosum. The current trial status is completed. This product is registered under clinical trial identifier NCT03137160. Target conditions include Pyoderma Gangrenosum.
What happened to similar drugs?
1 of 6 similar drugs in Pyoderma Gangrenosum were approved
Approved (1) Terminated (5) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05855967 | Approved | Completed |
| NCT04259346 | Phase 1 | Completed |
| NCT03942042 | Approved | Completed |
| NCT03848416 | Phase 1 | Completed |
| NCT03848403 | Phase 1 | Terminated |
| NCT03485976 | Phase 2 | Completed |
| NCT03099538 | Phase 2 | Completed |
| NCT03137160 | Phase 2 | Completed |
| NCT03073213 | Phase 1 | Completed |
| NCT02387801 | Phase 3 | Completed |
Competing Products
11 competing products in Pyoderma Gangrenosum
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| adalimumab | AbbVie | Phase 3 | 40 |
| sisomicin | Merck | Approved | 35 |
| secukinumab 150 mg (2 injections per dose | Novartis | Phase 2 | 27 |
| Secukinumab | Novartis | Phase 1/2 | 32 |
| Deucravacitinib | Bristol Myers Squibb | Phase 1 | 21 |
| gevokizumab | XOMA | Phase 2 | 25 |
| gevokizumab + Placebo + gevokizumab open-label | XOMA | Phase 3 | 22 |
| gevokizumab | XOMA | Phase 3 | 22 |
| gevokizumab + Placebo + gevokizumab open-label | XOMA | Phase 3 | 22 |
| vilobelimab + Placebo | InflaRx | Phase 3 | 22 |
| vilobelimab | InflaRx | Phase 2 | 25 |